Search

Displaying results 4401 - 4410 of 10000 in total
  1. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

  2. Drug

    Dimenoxadol

    go.drugbank.com/drugs/DB01461
    ExperimentalIllicit

    In the United States it is classified as a Schedule I controlled drug. … Dimenoxadol is an opioid analgesic which produces typical opioid effects such as analgesia and sedation. It is structurally similar to methadone and is a benzilic acid derivative.

  3. Drug

    Lefradafiban

    go.drugbank.com/drugs/DB04863
    Investigational

    Lefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.

  4. Drug

    Canfosfamide

    go.drugbank.com/drugs/DB04972
    Investigational

    Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.

  5. Drug

    Drostanolone propionate

    go.drugbank.com/drugs/DB14655
    ApprovedIllicit

  6. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]

  7. Drug

    8-azaguanine

    go.drugbank.com/drugs/DB01667
    Experimental

    It functions as an antimetabolite and is easily incorporated into ribonucleic acids.

    Synonyms: 8 AG
  8. Drug

    Carisoprodol

    go.drugbank.com/drugs/DB00395
    Approved

    In January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential … for abuse in addition to a low risk of dependence [L5074].

  9. Drug

    T611

    go.drugbank.com/drugs/DB06391
    Experimental

    T611 is an investigational oral anti-cytomegalovirus (CMV) drug candidate.

  10. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. … As of February 2007 the development of AZD3409 had been discontinued.